Waypra-Kid Tablet MD contains Lansoprazole 15mg, a proton pump inhibitor indicated for the treatment of acid-related gastrointestinal conditions in pediatric patients. Lansoprazole acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion. This reduction in gastric acidity promotes healing of erosive esophagitis, gastroesophageal reflux disease (GERD), and peptic ulcers, and provides symptomatic relief from heartburn and acid regurgitation. Waypra-Kid Tablet MD is specifically formulated for children, ensuring appropriate dosing and safety. It is indicated for short-term treatment of GERD, erosive esophagitis, and pathological hypersecretory conditions in pediatric patients aged 1 to 17 years. The tablet should be administered orally, preferably before meals, and dosing should be individualized based on the severity of the condition and patient response. Common adverse effects may include headache, abdominal pain, diarrhea, and nausea, which are generally mild and transient. Use of Lansoprazole in children requires careful consideration of contraindications such as hypersensitivity to Lansoprazole or other proton pump inhibitors. Long-term use should be monitored to prevent potential complications such as vitamin B12 deficiency or increased risk of gastrointestinal infections. Waypra-Kid Tablet MD offers an effective and well-tolerated option for managing pediatric acid-related disorders.